Mutations of androgen receptor gene in Brazilian patients with male pseudohermaphroditism

D.F. Cabral¹, A.T. Maciel-Guerra² and C. Hackel¹,²

Abstract

We describe the identification of point mutations in the androgen receptor gene in five Brazilian patients with female assignment and behavior. The eight exons of the gene were amplified by the polymerase chain reaction (PCR) and analyzed for single-strand conformation polymorphism (SSCP) to detect the mutations. Direct sequencing of the mutant PCR products demonstrated single transitions in three of these cases: G→A in case 1, within exon C, changing codon 615 from Arg to His; G→A in case 2, within exon E, changing codon 752 from Arg to Gln, and C→T in case 3, within exon B, but without amino acid change.

Research supported by FAPESP (No. 1996/3190-8) and FAEP-UNICAMP.

D.F. Cabral was the recipient of a CNPq fellowship.

Male pseudohermaphroditism is characterized by deficiency or absence of virilization in genetically male individuals (46,XY) with intra-abdominal or inguinal testes (1). The androgen insensitivity syndromes (AIS) are X-linked disorders which result from defects in the androgen receptor (AR) and are the most frequent cause of male pseudohermaphroditism. Phenotypic expression of AIS is quite variable: the complete form is characterized by a female phenotype while partial forms may be found in undermasculinized males or in normal males with infertility (2).

The AR is a member of the steroid hormone receptor superfamily of ligand-dependent transcription factors, and its protein comprises 919 amino acids. The androgen receptor gene is localized in the Xq11-12 region, spanning 90 kb and its approximately 2757-bp coding region is organized in 8 exons.

The complete cDNA sequence consists of 3.6 kb. The AR protein is divided into three distinct functional domains: the N-terminal domain (exon A), that has a role in transcriptional activation, the central domain (exons B and C), which consists of two zinc-finger elements responsible for DNA binding, and the C-terminal domain (exons D through H), responsible for androgen binding (3).

The heterogeneity in the phenotypic expression of AIS is due to a variety of androgen gene mutations which include deletions and point mutations, with the latter causing amino acid substitutions, premature termination of transcription and inappropriate splicing of RNA (4).

In the present study we report the results of molecular analysis of the androgen receptor gene in five unrelated subjects with a clinical diagnosis of complete androgen in-
sensitivity syndrome (CAIS). The five patients (Table 1) presented normal female external genitalia but a male karyotype (46,XY). Physical and hormonal features were consistent with CAIS and the gonads were testes.

Genomic DNA was isolated from patient leukocytes by standard methods. The eight exons of the gene were amplified by the polymerase chain reaction (PCR) and screened for single-strand conformation polymorphism (SSCP) to identify mutations. PCR was performed using 11 sets of primers (5,6). The exon A coding sequence was subdivided into four overlapping fragments due to its large size (1613 bp).

Since SSCP is more sensitive for fragments of less than 350 bp, the PCR products of the three fragments from exon A and from exon D were cleaved with appropriate restriction enzymes prior to electrophoresis. The denatured PCR products were run on non-denaturing 12.5 and 20% polyacrylamide Phastgel in the absence of glycerol using the Pharmacia PhastSystem (Uppsala, Sweden). Electrophoresis was carried out at either 15 or 20°C for 2 h at 150 V, and the gels were silver-stained.

Band-shifts in SSCP gels were detected in three cases, on exons B, C and E. Direct sequencing was performed with PCR products from two separate reactions using the sense and antisense primers labelled with γ P32-ATP and the Thermosequenase kit (Amersham Life Science Inc., Cleveland, OH). The sequencing of the putative mutant segments revealed G→A transitions in two instances: at position 2348 (exon C) in case 1, resulting in the Arg615His substitution (Figure 1A), and at position 3136 (exon E) in case 2, resulting in the Arg752Gln substitution (Figure 1B). In case 3, a cytosine to thymine mutation at nucleotide 1989 (exon B) was found, but this substitution did not result in amino acid changes (Ala585Ala).

We have encountered some difficulties in the amplification and SSCP analysis of exon A, since these regions contain a highly polymorphic polyglutamine (CAG) stretch and a highly GC-rich segment encoding a polglycine stretch. Two polymorphisms were studied in this exon: the number of CAG repeats and the StuI restriction enzyme polymorphism (7,8). The number of CAG repeats varied from 18 to 24, being within the normal range (9). The analysis of StuI polymorphism showed that all patients were positive for this restriction enzyme site, which is the most frequent allele in American Caucasian males (8).

To date, 245 mutations were described in the androgen receptor gene that give rise to AIS. A regular data base has been compiled and updated by Gottlieb et al. (10) and is available from EMBL (http://www.mcgill.ca/androgendb).

Most of the mutations identified in the AR gene are different, with very few patients sharing the same mutation. The same mutation can be associated with different phenotypes not only from different families but even within the same family. The distribution of androgen receptor gene mutations is interesting also for the clustering of mutations in specific areas of the receptor protein in or around exons E and G, as well as for the paucity of mutations that have been localized on exon A. Only mutations in exons B and C have an expected phenotype, which is almost always related to CAIS (11).

The Arg615His substitution (case 1) has already been described in CAIS patients (12-

**Table 1 - Age at diagnosis and familial recurrence status of the five CAIS patients.**

<table>
<thead>
<tr>
<th>Subject</th>
<th>Age (years)</th>
<th>Familial recurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>26</td>
<td>sister and maternal aunt</td>
</tr>
<tr>
<td>2</td>
<td>16</td>
<td>none</td>
</tr>
<tr>
<td>3</td>
<td>21</td>
<td>sister and maternal aunt</td>
</tr>
<tr>
<td>4</td>
<td>14</td>
<td>none</td>
</tr>
<tr>
<td>5</td>
<td>2</td>
<td>two maternal aunts (*)</td>
</tr>
</tbody>
</table>

*One of the two maternal aunts of subject 5 was previously examined by us.*
Androgen receptor gene mutations

This mutation prevents the androgen receptor from binding the androgen responsive element (ARE) consensus and abolishes its transactivational competence in vitro, being probably sufficient to cause complete AIS (13).

The Arg752Gln substitution (case 2) has also been detected in patients from two families (16,17). Evans (16) reported the absence of hormone-receptor binding on genital skin fibroblasts from one of these patients. According to this author, this mutation is identical and functionally equivalent to that observed at amino acid 734 of the rat androgen receptor in rat testicular feminization. Mutations in exon E represent about 40% of all molecular alterations involving amino acid changes described in the hormone-binding domain (3).

Since the detection rate for SSCP is estimated to be 70 to 80% (6), exons B to H from cases 3, 4 and 5 were completely sequenced to exclude the existence of mutations in these regions, and none were found. However, undetected mutations may still exist in exon A, not sequenced in this study, or may be related to the androgen receptor gene promoter (18). Somatic mosaicism may also be postulated since genomic DNA was isolated from leukocytes, and not from tissues where the AR gene is expressed, like genital skin (19).

There is still the possibility that some mutations were missed by the screening procedure, although some cases may be the result of other, as yet undefined, genetic lesions (20).
References


